Teva's ecopipam secures FDA priority review for pediatric Tourette syndrome, potentially bringing the first new therapy in over a decade.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday's premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.

Teva's stock gains reflect stronger branded drug growth, a strengthening pipeline and improving finances, but generics and debt remain key risks.

PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for ecopipam, with a targeted action (PDUFA) date late in the first quarter of 2027. Ecopipam is a first-in-class investigational therapy for the treatment of pediatric patients with Tourette syndrome. This milestone advances Teva's Pivot to Growth strategy by utilizing the company's expertise in neuroscience to support patients, particularly in areas where there is high unmet need.

Health insurer Humana has ‌agreed not to refer to drugmaker Teva as an Israeli company at an upcoming U.S. drug price-fixing trial, after the drugmaker said public views on the Gaza war could unfairly influence jurors.

Cetera Investment Advisers grew its holdings in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 44.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 87,216 shares of the company's stock after acquiring an additional 26,789 shares during the period. Cetera Investment

Assenagon Asset Management S.A. lifted its holdings in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 128.1% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 3,056,017 shares of the company's stock after purchasing an additional 1,716,315 shares during the period. Assenagon Asset Management S.A. owned about

Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Supernus Pharmaceuticals (SUPN) and Teva Pharmaceutical Industries Ltd. (TEVA). But which of these two stocks is more attractive to value investors?

Teva Pharmaceuticals has asked a U.S. judge to ​prevent insurer Humana from telling jurors it is an Israeli company at a major drug ‌price-fixing trial, arguing that strong public views over the Gaza war could prejudice proceedings and affect its ability to receive a fair hearing.